Long-Term Mortality Risk Low After Cerebral Vein Thrombosis

Share this content:
Long-Term Mortality Risk Low After Cerebral Vein Thrombosis
Long-Term Mortality Risk Low After Cerebral Vein Thrombosis

(HealthDay News) – For patients who survive a cerebral vein thrombosis (CVT), the long-term risk of mortality and recurrent venous thromboembolism (VTE) seems to be low.

Francesco Dentali, MD, from the University of Insubria in Varese, Italy, and colleagues retrospectively assessed long-term mortality rates, residual disability, and recurrent VTE in an international cohort of 706 patients (73.7% female) with a first CVT episode who were followed for a median of 40 months (range, 6–297 months).

Over the follow-up period, the researchers found that 2.8% of patients died, 89.1% had a complete recovery (modified Rankin Score [mRS], 0–1), and 3.8% had a partial recovery and were independent (mRS, 2). The mean treatment duration was 12 months, during which time 84% of patients were treated with oral anticoagulants. CVT recurred in 4.4% of patients, and 6.5% had VTE in a different site, corresponding with an overall incidence of recurrence of 23.6 events per 1,000 patient-years and of 35.1 events per 1,000 patient years after anticoagulant therapy withdrawal. The only significant predictor of recurrence in multivariate analysis was a previous VTE (hazard ratio, 2.70).

"The long-term risk of mortality and recurrent VTE appears to be low in patients who survived the acute phase of CVT," the authors write.

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs